Life Science Investing Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint 24 September
Life Science Investing Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology 12 September
Life Science Investing Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 08 September
